- |||||||||| Lemtrada (alemtuzumab) / Sanofi
Predictors of response to high-efficacy therapies in relapsing-remitting multiple sclerosis (Poster Exhibition) - Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_701;
Our study suggests that the presence of ≥ 2 clinical or radiological markers of disease activity (score ≥ 2) during the first year of high-efficacy treatment reduces the odds of remaining disease-free at 3-year follow-up. Studies with larger samples are necessary to achieve conclusive results.
- |||||||||| Campath (alemtuzumab) / Sanofi, Rituxan (rituximab) / Roche, Biogen, Lemtrada (alemtuzumab) / Sanofi
Autoimmune encephalitis with CSF anti-GluR3 antibodies after alemtuzumab treatment: a case report (Poster Exhibition) - Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_667;
First-line immune therapies in AE consist of corticosteroids (intravenous and oral), sometimes with intravenous immunoglobulin (IVIG) and/or plasma exchange (PE). Second-line treatments are administered when the first-line therapies fail to produce adequate benefit, or when the disease is severe or relapsing, including rituximab, cyclophosphamide, azathioprine, mycophenolate mofetil.
- |||||||||| Tecfidera (dimethyl fumarate) / Biogen, Mavenclad (cladribine) / EMD Serono, Zinbryta (daclizumab) / Biogen, AbbVie
Non-interventional, prospective study CLEVER (CLadribine Tablets - EValuation of thERapy satisfaction), data extraction March 2019 (Poster Exhibition) - Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_652;
First line therapies (Glatirameracetate, Interferons, Teriflunomid and Dimethylfumarate) were switched by 50,5% of CLEVER patients, second line therapies (Daclizumab, Fingolimod, Natalizumab, Alemtuzumab) by 41,6%... The reported AEs are in line with the known safety profile of Cladribine Tablets.The presented data from this NIS will provide new insights into the real-world usage of Cladribine Tablets in patients with RMS.
- |||||||||| The Burden of Treatment Monitoring for Patients and Physicians in Multiple Sclerosis (MS) in Europe and The United States (Poster Exhibition) - Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_649;
57% of HCPs in 5EU and 57% in US, associated platform injectables (Interferons and glatiramer acetate) with low monitoring burden compared to 11% (5EU) and 11% (US) who associate this with the mAbs (alemtuzumab, natalizumab, ocrelizumab) and 19% (5EU) and 23% (US) with the orals (fingolimod, dimethyl fumarate, teriflunomide, cladribine (5EU only))...However, for patients, monitoring is a reassurance. This highlights a potential disconnect between HCP and patient perceptions that could be impacting treatment choice and, as such, warrants further investigation.
- |||||||||| Tecfidera (dimethyl fumarate) / Biogen, Rituxan (rituximab) / Roche, Biogen, Lemtrada (alemtuzumab) / Sanofi
Loss of MEDA under two standard treatment sequences in relapsing-remitting Multiple Sclerosis (Poster Exhibition) - Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_620;
DMF to FTY seem to be an efficacious treatment sequence because here we found the lowest number of “Loss of MEDA” patients during an eight year observation period. These results may help select the adequate DMT treatment sequence for patients with RR-MS.
- |||||||||| Tecfidera (dimethyl fumarate) / Biogen, Lemtrada (alemtuzumab) / Sanofi
Do real world studies include real world patients in MS? (Poster Exhibition) - Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_488;
We did not observe significant differences in clinical and demographic aspects of included patients in RCCT and RWS. More studies that include all the diversity of the spectrum of MS patients followed in clinical practice are needed to better understand the effectiveness and safety profile of old and new MS treatments in patients different from the ones that entered to RCCT
- |||||||||| Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
Alemtuzumab Infusion-associated reactions are not related to infusion rate (Poster Exhibition) - Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_475;
In our experience, Alemtuzumab IAR incidence and types are not related with the infusion rate, but are more frequent during the first course, independently of infusion rate. The fast rate infusion is equally safe and shortens the patient's hospital stay.
- |||||||||| Tysabri (natalizumab) / Biogen, Tecfidera (dimethyl fumarate) / Biogen
Treatment choice after Natalizumab discontinuation: results from an Italian multicenter retrospective study (Poster Exhibition) - Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_440;
Out of them, 2,483 (45.3%) discontinued NTZ treatment; 1000 (40.3%) were then treated with fingolimod, 483 (19.5%) with glatiramer acetate, 308 (12.4%) with interferons, 224 (9.0%) with other immunosuppressive drugs, 224 (9.0%) with dimethyl fumarate, 137 (5.5%) with alemtuzumab, and 107 (4.3%) with teriflunomide. Stratifying according to the age at NTZ initiation, we found that patients older than 40 years and patients with EDSS higher than 4.0, were treated more frequently with interferons compared to patients younger than 40 and to patients with EDSS lower than 4.0 (227 [17.8%] versus 81 [6.7%], p< 0.05; 253 [21.7] versus 55 [4.2], p< 0.05, respectively).
- |||||||||| Lemtrada (alemtuzumab) / Sanofi
Lymphocyte changes induces by alemtuzumab in multiple sclerosis patients (Poster Exhibition) - Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_418;
Stratifying according to the age at NTZ initiation, we found that patients older than 40 years and patients with EDSS higher than 4.0, were treated more frequently with interferons compared to patients younger than 40 and to patients with EDSS lower than 4.0 (227 [17.8%] versus 81 [6.7%], p< 0.05; 253 [21.7] versus 55 [4.2], p< 0.05, respectively). Alemtuzumab treatment induces an increase in regulatory NK cells and a decrease in effector cells and in proinflammatory cytokine production.
- |||||||||| Tecfidera (dimethyl fumarate) / Biogen, Lemtrada (alemtuzumab) / Sanofi
DMTs Drop out analysis: 10 years follow-up in a cohort of relapsing-remitting multiple sclerosis patients in Argentina (Poster Exhibition) - Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_354;
352 DMS patients treated with at least one of the available DMTs:Interferons(IFNs),GlatiramerAcetate(GA),Fingolimod(FTY),Teriflunomide(TRF),Dimethylfumarate(DMF),Alemtuzumab(ALZ),Natalizumab(NTZ)... After 10years of F-U,59% patients remain on their first therapy.41% stopped treatment.LoE and SAE were the main reasons of discontinuation.97% had LTFU.These results confirm that efficacy, tolerability and close LTFU have strong influence in adherence to treatment.
- |||||||||| Lemtrada (alemtuzumab) / Sanofi
Disability improvement after alemtuzumab is associated with T2 lesion volume shrinkage in multiple sclerosis (Poster Exhibition) - Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_343;
After 10years of F-U,59% patients remain on their first therapy.41% stopped treatment.LoE and SAE were the main reasons of discontinuation.97% had LTFU.These results confirm that efficacy, tolerability and close LTFU have strong influence in adherence to treatment. Our findings suggest that the strong and prolonged anti-inflammatory effect promoted by alemtuzumab might have enhanced endogenous recovery mechanisms, in the subgroup of patients with disability reduction.
- |||||||||| Rituxan (rituximab) / Roche, Biogen, Lemtrada (alemtuzumab) / Sanofi
Intrathecal IgG and IgM synthesis are strongly associated with the use of highly effective therapies in relapsing MS in the Swiss MS Cohort Study (Poster Exhibition) - Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_341;
According to currently applied algorithms in Switzerland Ocrelizumab, Rituximab, Natalizumab and Alemtuzumab (highly effective disease modifying treatments, heDMT) are initiated in patients with high activity or insufficient response to previous DMTs. Both intrathecal IgG and IgM synthesis are associated with more frequent and earlier use of highly effective therapies in RRMS supporting their value as biomarkers of high disease activity and severity.
- |||||||||| Tecfidera (dimethyl fumarate) / Biogen, Lemtrada (alemtuzumab) / Sanofi
TREAT-MS study of real-world effectiveness of alemtuzumab in RRMS patients in Germany: subgroup analysis by number of prior disease-modifying therapies (Poster Exhibition) - Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_335;
Treatments immediately prior to enrolment were fingolimod (21.6%), natalizumab (14.9%), IFNB preparations (9.0%), dimethyl fumarate (8.2%), glatiramer acetate (5.8%), teriflunomide (2.2%), other/unknown (23.6%), or none (14.8%)... These interim analyses show stable EDSS scores and reduced relapses with alemtuzumab regardless of number of prior DMTs, and support registration trial findings in real-world patients with longer disease duration and varied treatment history.
- |||||||||| Lemtrada (alemtuzumab) / Sanofi
Safety and efficacy of various DMTs in MS patients who failed Alemtuzumab Therapy (Poster Exhibition) - Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_334;
Limitations: Our study represents real world data with a small number of subjects and variable duration of treatment. The results of the study suggests that patients who demonstrate evidence of disease activity on Alemtuzumab therapy can be safely transitioned to Ocrelizumab therapy with acceptable efficacy and safety profile.
- |||||||||| Tecfidera (dimethyl fumarate) / Biogen, Lemtrada (alemtuzumab) / Sanofi
Clinical and patient reported outcomes in multiple sclerosis patients on disease modifying therapies (Poster Exhibition) - Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_289;
This study shows that low efficacy treatment can be effective for some patients with no significant increase in EDSS or worsening of patient reported outcomes over 10 years. The higher efficacy treatments produce a greater reduction in EDSS and GNDS, as well as an increase in LMSQoL scores demonstrating an improvement in patient reported well-being.
- |||||||||| Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe, Lemtrada (alemtuzumab) / Sanofi
A nationwide study of fingolimod for the treatment of multiple sclerosis (Poster Exhibition) - Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_283;
Almost one third of patients were previously treated with natalizumab. 38% discontinued therapy; adverse events were the most common reason for discontinuation followed by lack of efficacy and pregnancy plans.
- |||||||||| Lemtrada (alemtuzumab) / Sanofi
Journal: Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis. (Pubmed Central) - Aug 23, 2019
Furthermore, we found a positive correlation between CD20+ T cells in the CSF and multiple sclerosis disease severity and see that regulation of CD20+ T cells likely contributes to the positive treatment effect of the multiple sclerosis treatment alemtuzumab. These data represent an important contribution to the understanding of the nature of CD20+ T cells and strongly suggests a role of CD20+ T cells in the pathogenesis of multiple sclerosis.
- |||||||||| Lemtrada (alemtuzumab) / Sanofi
Clinical, Journal: Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab. (Pubmed Central) - Aug 15, 2019
In cases seen to date, early and conservative treatment resulted in good clinical outcome, although the natural history of AAC in this population without critical illness is not well defined. Awareness of this safety risk by general and specialty neurologists is important for prompt recognition and optimal management.
- |||||||||| Tecfidera (dimethyl fumarate) / Biogen, Zinbryta (daclizumab) / Biogen, AbbVie, Lemtrada (alemtuzumab) / Sanofi
Clinical, Review, Journal: Preapproval and postapproval evidence on drugs for multiple sclerosis. (Pubmed Central) - Aug 15, 2019
No abstract available The lack of comparative evidence and data on clinical effectiveness hamper the assessment of therapeutic value and place in therapy of drugs approved for MS.
- |||||||||| Review, Journal: New aspects of immunotherapy in multiple sclerosis (Pubmed Central) - Aug 15, 2019
During recent months, special attention was paid to the new progressive multifocal leukoencephalopathy (PML) risk assessment in natalizumab-treated patients, cardiac side effects of fingolimod, cases of idiopathic thrombocytopenic purpura and listeria meningitis associated with alemtuzumab and cases of daclizumab-treated patients with liver failure or encephalitis. These case reports highlight the importance of careful monitoring of all patients treated with immunomodulatory therapies.
- |||||||||| Lemtrada (alemtuzumab) / Sanofi
Clinical, Journal: Clinical Pharmacology of Alemtuzumab, an Anti-CD52 Immunomodulator, in Multiple Sclerosis. (Pubmed Central) - Aug 15, 2019
No effects of age, race, or gender on the pharmacokinetics or pharmacodynamics were observed. Together, the pharmacokinetics, pharmacodynamics and immunogenicity results support the continued development and use of alemtuzumab for the treatment of MS, and likely explain its sustained effects beyond the dosing interval.
- |||||||||| Lemtrada (alemtuzumab) / Sanofi
Clinical, Journal: Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report. (Pubmed Central) - Aug 15, 2019
This is the first published report of diffuse alveolar bleeding in a patient with multiple sclerosis treated with alemtuzumab. Four similar cases in patients treated for multiple sclerosis and several fatal cases in patients treated for other conditions are registered at the World Health Organization database of suspected adverse events (VIgiBas
- |||||||||| cladribine / Generic mfg., Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Biomarker, Clinical, Review, Journal, IO biomarker: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. (Pubmed Central) - Aug 7, 2019
For people with primary progressive MS, ocrelizumab is probably more effective than placebo (in-study disease progression)...Cladribine, immunoglobulins, IFN-β-1a 30 μg intramuscular weekly, IFN-β-1b subcutaneous alternate day, and teriflunomide are probably more effective than placebo in decreasing risk of conversion to MS. Suggestions for future research include studies considering comparative effectiveness, usefulness of high-efficacy treatment vs stepped-care protocols, and research into predictive biomarkers.
- |||||||||| Journal: Siponimod (Mayzent)--a new drug for multiple sclerosis. (Pubmed Central) - Aug 6, 2019
Suggestions for future research include studies considering comparative effectiveness, usefulness of high-efficacy treatment vs stepped-care protocols, and research into predictive biomarkers. No abstract available
|
